Eli Lilly and Company
LLY
$1,189.41
-$44.25-3.59%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 79.67B | 72.25B | 65.18B | 59.42B | 53.26B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 79.67B | 72.25B | 65.18B | 59.42B | 53.26B |
| Cost of Revenue | 13.23B | 12.41B | 11.05B | 10.08B | 9.25B |
| Gross Profit | 66.44B | 59.84B | 54.13B | 49.34B | 44.01B |
| SG&A Expenses | 12.45B | 11.77B | 11.31B | 10.62B | 9.98B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.27B | 38.29B | 35.70B | 33.26B | 31.05B |
| Operating Income | 39.40B | 33.96B | 29.48B | 26.16B | 22.21B |
| Income Before Tax | 33.60B | 31.13B | 25.73B | 22.50B | 16.86B |
| Income Tax Expenses | 6.88B | 5.85B | 5.09B | 4.09B | 3.06B |
| Earnings from Continuing Operations | 26.71K | 25.28K | 20.64K | 18.41K | 13.80K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.71B | 25.28B | 20.64B | 18.41B | 13.80B |
| EBIT | 39.40B | 33.96B | 29.48B | 26.16B | 22.21B |
| EBITDA | 41.50B | 36.00B | 31.48B | 28.06B | 24.10B |
| EPS Basic | 29.83 | 28.19 | 22.99 | 20.48 | 15.33 |
| Normalized Basic EPS | 27.61 | 23.52 | 20.25 | 17.90 | 15.22 |
| EPS Diluted | 29.80 | 28.15 | 22.95 | 20.44 | 15.30 |
| Normalized Diluted EPS | 27.57 | 23.49 | 20.22 | 17.87 | 15.19 |
| Average Basic Shares Outstanding | 3.58B | 3.59B | 3.59B | 3.60B | 3.60B |
| Average Diluted Shares Outstanding | 3.59B | 3.59B | 3.60B | 3.60B | 3.61B |
| Dividend Per Share | 6.46 | 6.23 | 6.00 | 5.80 | 5.60 |
| Payout Ratio | 21.66% | 22.10% | 26.08% | 28.28% | 36.46% |